Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP1177 | DOI: 10.1530/endoabs.49.EP1177

1Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal; 2Centro Hospitalar Lisboa Norte, Lisboa, Portugal.


Introduction: Testosterone treatment in patients with hypogonadism has been associated with cardiovascular and prostatic complications.

Objective: To describe the evolution of analytical parameters associated to the complications of testosterone treatment in a male population with hypogonadism treated with testosterone. Methods A retrospective, longitudinal study in which the clinical data of male adults with hypogonadism under intramuscular testosterone therapy were analysed in 2 tertiary centres. The duration and doses of testosterone were recorded. Haematocrit (Hct), total cholesterol (TC), LDL cholesterol (c-LDL), total prostate-specific antigen (PSA) and total testosterone levels were assessed at the beginning and at the end of follow-up. Paired-t-test was used to compare means and the results are shown in mean and standard deviation.

Results: We analysed 128 patients, 35% primary and 65% secondary hypogonadism. The mean age was 49.6±17.3 years. The follow-up time was 2.6 years (0.6–9.4 years). The mean interval between injections was 4.4±2.3 weeks. The final testosterone was 392.0±112.7 ng/dl. The results are summarized in the table below: Treatment with testosterone resulted in increased Hct and PSA values, however only the Hct difference proved statistically significant. Spearman correlation test revealed a positive and statistically significant correlation between the increase of testosterone levels and the increase of Hct (r=0.21; P=0.03). No hospitalizations for cardiovascular events were reported.

Hct (%)TC (mg/dl)C-LDL (mg/dl)PSA (ng/ml)
First measurement42.9±5.0194.3±41.5114.1±37.31.4±1.7
Final measurement44.0±4.4191.7±30.2110.8±28.31.7±2.4
Difference1.1±4.4−2.6±38.2−3.4±34.80.3±1.6
P-values0.010.680.600.30

Discussion: The rise of Hct, although statistically significant, was low. The remaining parameters did not show statistically significant increases so testosterone therapy appears to be safe from a cardiovascular and prostatic perspective.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.